Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

David J. Straus, Monika Długosz-Danecka, Joseph M. Connors, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Javier Munoz, Hun Ju Lee, Won Seog Kim, Ranjana Advani, Stephen M. AnsellAnas Younes, Andrea Gallamini, Rachael Liu, Meredith Little, Keenan Fenton, Michelle Fanale, John Radford

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences